Skip to main content

Table 2 The process indicators of screening, stratified by the age, gender, and the brands of PG testing

From: Brand interchangeability of pepsinogen tests in the real-world setting after eradication of Helicobacter pylori: a community-based study

Brands of PG test Participants, no Positive test, no Positivity rate (%) Endoscopic examination, no Referral rate for endoscopic examination (%)
Test 1 Test 2 Test 1 + 2 Test 1 Test 2 Test 1 + 2 Test 1 Test 2 Test 1 + 2 Test 1 Test 2 Test 1 + 2
Male
 30–49 years 842 17 29 37 2.0 3.4 4.4 10 9 15 58.8 31.0 40.5
 ≥ 50 years 1668 85 93 109 5.1 5.6 6.5 34 36 43 40.0 38.7 39.4
Subtotal 2510 102 122 146 4.1 4.9 5.8 44 45 58 43.1 36.9 39.7
Female
 30–49 years 1006 24 36 46 2.4 3.6 4.6 8 8 12 33.3 22.2 26.1
 ≥ 50 years 1601 66 75 92 4.1 4.7 5.7 27 26 35 40.9 34.7 38.0
Subtotal 2607 90 111 138 3.5 4.3 5.3 35 34 47 38.9 30.6 34.1
Both sexes
 30–49 years 1848 41 65 83 2.2 3.5 4.5 18 17 27 43.9 26.2 32.5
 ≥ 50 years 3269 151 168 201 4.6 5.1 6.1 61 62 78 40.4 36.9 38.8
Total 5117 192 233 284 3.8 4.6 5.6 79 79 105 41.1 33.9 37.0
  1. PG, pepsinogen; Test 1, GastroPanel (Biohit HealthCare, Helsinki, Finland); Test 2, LZ-Test (Eiken Chemical Co., Ltd, Tokyo, Japan); Test 1 + 2, two tests in parallel
  2. *Test 1 + 2 indicated the parallel combination of two tests (either one of the two tests was positive)
  3. P < 0.05 in the comparison between test 1 and test 2